Close Menu

NEW YORK – Coralville, Iowa-based FBB Biomed is developing a COVID-19 blood test for RNA biomarkers that it says will be able to predict how severely ill someone infected with SARS-CoV-2 will become from the disease.

The test would "provide physicians an answer to whether the patient is going to proceed to severe disease," CEO and Cofounder Howard Urnovitz said.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.